<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Exicure, Inc.

    verified_userVerify Profile
    Companies » Health Care » Pharmaceuticals & Biotechnology » Pharmaceuticals

    About Exicure, Inc.

    Exicure, Inc. is a clinical stage biotechnology company developing a new class of immunomodulatory and gene regulating drugs against validated targets. Exicure's proprietary 3-dimensional, spherical nucleic acid (SNA™) architecture unlocks the potential of therapeutic oligonucleotides in a wide range of cells and tissues. Exicure's lead programs address oncology, inflammatory diseases and genetic disorders. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      David A. Giljohann
    • FOUNDED
      2009
    • EMPLOYEES
      20
    • SECTOR
      Pharmaceuticals & Biotechnology
    • SUBSECTOR
      Pharmaceuticals

    Company Tags

    No articles found.

    Lab Sensor Solutions, Inc.

    Lab Sensor Solutions, Inc.

    Lab Sensor Solutions’ mission is to improve lives through the use of real-time s...

    Lab Sensor Solutions’ mission is to improve l...

    Fundraising Status:    EC
    Filing Type:    CF
    Vir Biotechnology, Inc.

    Vir Biotechnology, Inc.

    Vir integrates diverse innovations in science, technology, and medicine to transfo...

    Vir integrates diverse innovations in science, ...

    Filing Type:    PU
    Arcturus Therapeutics Holdings Inc.

    Arcturus Therapeutics Holdings Inc.

    Arcturus Therapeutics is developing portfolio of RNA therapeutics for treatment of...

    Arcturus Therapeutics is developing portfolio o...

    Filing Type:    PU
    Daiichi Sankyo Co., Ltd.

    Daiichi Sankyo Co., Ltd.

    Founded on September 28, 2005 through the merger of Daiichi Pharmaceutical and San...

    Founded on September 28, 2005 through the merge...

    Filing Type:    PU
    WAVE Life Sciences Ltd.

    WAVE Life Sciences Ltd.

    We are a biotechnology company focused on delivering transformational therapies fo...

    We are a biotechnology company focused on deliv...

    Filing Type:    PU
    Neon Therapeutics, Inc.

    Neon Therapeutics, Inc.

    Neon Therapeutics is a clinical-stage immuno-oncology company leading in the field...

    Neon Therapeutics is a clinical-stage immuno-on...

    Filing Type:    PU
    20/20 GeneSystems, Inc.

    20/20 GeneSystems, Inc.

    20/20 GeneSystems, Inc. an early stage digital diagnostics company with the core m...

    20/20 GeneSystems, Inc. an early stage digital ...

    Fundraising Status:    SASBEC
    Filing Type:    RA
    Turning Point Therapeutics, Inc.

    Turning Point Therapeutics, Inc.

    Turning Point Therapeutics is a clinical-stage precision oncology company with a p...

    Turning Point Therapeutics is a clinical-stage ...

    Filing Type:    PU
    Champions Oncology, Inc.

    Champions Oncology, Inc.

    Champions Oncology, Inc. is engaged in the development of advanced technology solu...

    Champions Oncology, Inc. is engaged in the deve...

    Filing Type:    PU
    Gossamer Bio, Inc.

    Gossamer Bio, Inc.

    Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering,...

    Gossamer Bio is a clinical-stage biopharmaceuti...

    Filing Type:    PU
    Theravance Biopharma, Inc.

    Theravance Biopharma, Inc.

    Theravance Biopharma is a diversified biopharmaceutical company with the core purp...

    Theravance Biopharma is a diversified biopharma...

    Filing Type:    PU
    Viela Bio, Inc.

    Viela Bio, Inc.

    Viela is dedicated to the development and commercialization of novel, life-changin...

    Viela is dedicated to the development and comme...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.